The Joint Committee on Vaccination and Immunisation (JCVI) is calling for evidence to support a review of possible modifications to the Human Papillomavirus (HPV) immunisation programme. The programme currently provides the offer of immunisation routinely to girls aged 12 to 13 years.
To inform this review, the JCVI, which provides independent expert advice on immunisation to Government, welcomes relevant evidence from interested parties.
Interested parties wishing to provide evidence relevant to the issues set out below should provide the information in a written submission. Submissions should be sent no later than 9 November 2012 to the JCVI mailbox.
Issues under consideration
JCVI is interested in relevant evidence to support consideration of these issues:
- 2-dose schedules for HPV vaccine
- potential benefits of HPV vaccine for those not currently offered immunisation, particularly men who have sex with men (MSM)
- vaccines that offer protection against a larger number of HPV types
The JCVI aims to consider data on the following to inform epidemiological and economic modelling work:
- What impact would reductions from a 3-dose to a 2-dose (0 and 6 month) schedule have on the benefits of immunisation, in particular a) the duration of protection, b) the cross-protection against non-vaccine types, and c) uptake?
- What evidence is there on the impact of the current HPV vaccination programme in groups directly targeted and not directly targeted by vaccination?
- As the current HPV vaccination programme may be of less benefit to MSM, what is the prevalence and incidence of various HPV type infections in MSM by age, what impact does HPV have on development of disease in this group and what is the impact of co-infection with HIV, and how acceptable and feasible is targeted HPV immunisation for MSM?
- HPV vaccination can potentially provide protection against a wider range of HPV-related diseases. What evidence is there about the natural history, potential vaccine impact and UK burden (health and economic) of HPV-related diseases besides cervical cancer?
- What evidence is there about the burden of diseases caused by HPV types other than HPV 6, 11, 16 and 18, and about the potential impact of higher valency vaccines?
Details of the call
To inform its considerations, the JCVI welcomes submissions from interested parties of good quality scientific, medical, social research or economic evidence relevant to the issues under consideration. Submissions should reference peer-reviewed published material wherever possible.
As JCVI is committed to making as much of its work open to public scrutiny as possible, the committee aims to publish the evidence and information considered in its meetings as a matter of course. Exceptions (where there are reasons to withhold particular papers from publication) will be decided in line with exemptions available under the Freedom of Information (FOI) Act. Submissions should indicate where any data should be withheld from publication and the reasons for this in line with exemptions applicable under the FOI Act (see paragraphs 65 - 80 of the JCVI Code of Practice).
Epidemiological and economic analysis submissions will be shared in confidence with the Health Protection Agency to inform papers and cost analysis conducted on behalf of the JCVI.
All submissions will be acknowledged and will be provided to the JCVI to help formulate its advice; the latter will be published in minutes of the JCVI. More information about how JCVI develops and formulates its advice can be found in the